Drugs / MEOPA
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05821517 Comparator | Dec 2023 → Dec 2026 expected | — | Centre Hospitalier Universitaire de Nice | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEOPA | “Inhaled equimolar mixture of oxygen and notrous oxyde (MEOPA) at a 15L/min flux is administered concomitantly to the reduction procedure.” NCT05821517 ↗ |
| Route | Inhaled | “Inhaled equimolar mixture of oxygen and notrous oxyde (MEOPA)” NCT05821517 ↗ |